scispace - formally typeset
Open AccessJournal ArticleDOI

Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol.

TLDR
The present observations suggest that the anti-transformation effects of radicicol may be mediated, at least in part, by the association of Radicicol with HSP90 and the consequent dissociation of the Raf/HSP90 complex leading to the attenuation of the Ras/MAP kinase signal transduction pathway.
Abstract
Radicicol, a macrocyclic anti-fungal antibiotic, has the ability to suppress transformation by diverse oncogenes such as Src, Ras and Mos. Despite this useful property, the mechanism by which radicicol exerts its anti-transformation effects is currently unknown. To understand the transformation-suppressing effects of radicicol, a biotinylated derivative of radicicol was chemically synthesized and used as a probe in a Western-blot format to visualize cellular proteins that interact with radicicol. In transformed and untransformed mouse fibroblasts, the most prominent cellular protein that bound to radicicol had a molecular weight of approximately 90 kDa. Further analysis revealed that this protein was the mouse homologue of the 90 kDa heat shock protein (HSP90). This was confirmed by demonstrating the ability of radicicol to specifically bind purified human HSP90. Specificity of binding was demonstrated by the inhibition of binding of biotinylated radicicol by the native drug. Taken together with other studies the present observations suggest that the anti-transformation effects of radicicol may be mediated, at least in part, by the association of radicicol with HSP90 and the consequent dissociation of the Raf/HSP90 complex leading to the attenuation of the Ras/MAP kinase signal transduction pathway.

read more

Citations
More filters
Journal ArticleDOI

Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death

TL;DR: Some of the molecular and cellular events initiated by cell stress-the interrelationships between stress signaling, cell death, and oncogenesis-and chaperones as potential targets for cancer diagnosis and treatment are addressed.
Journal ArticleDOI

The HSP90 chaperone machinery

TL;DR: Owing to the importance of HSP90 in the regulation of many cellular proteins, it has become a promising drug target for the treatment of several diseases, which include cancer and diseases associated with protein misfolding.
Journal ArticleDOI

Hsp90 molecular chaperone inhibitors: are we there yet?

TL;DR: Success will likely lie in treating cancers that are addicted to particular driver oncogene products that are sensitive Hsp90 clients, as well as malignancies in which buffering of proteotoxic stress is critical for survival.
Journal ArticleDOI

Hsp90 inhibitors as novel cancer chemotherapeutic agents

TL;DR: Because of the chemoprotective activity of several proteins that are Hsp90 clients, the combination of an HSp90 inhibitor with a standard chemotherapeutic agent could dramatically increase the in vivo efficacy of the therapeutic agent.
Journal ArticleDOI

Heat shock protein 90 as a molecular target for cancer therapeutics.

TL;DR: It is apparent that Hsp90 inhibitors are unique in that, although they are directed toward a specific molecular target, they simultaneously inhibit multiple signaling pathways on which cancer cells depend for growth and survival, thereby perhaps circumventing the characteristic genetic plasticity of cancer cells.
References
More filters
Journal ArticleDOI

Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.

TL;DR: It is shown that radicicol, a macrocyclic antifungal structurally unrelated to geldanamycin, also specifically binds to Hsp90, and represents a structurally unique antibiotic, and the first non-benzoquinone ansamycin capable of binding to HSp90 and interfering with its function.
Related Papers (5)